Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prolyl Hydroxylase 3 Knockdown Accelerates VHL-Mutant Kidney Cancer Growth In Vivo.

International journal of molecular sciences - 11 Mar 2021

Zacharias Niki M, Wang Lei, Maity Tapati, Li Li, Millward Steven W, Karam Jose A, Wood Christopher G, Navai Neema

Abstract excerpt

Von Hippel Lindau (VHL) inactivation, which is common in clear cell renal cell carcinoma (ccRCC), leads directly to the disruption of oxygen homoeostasis. VHL works through hypoxia-inducible factors (HIFs). Within this VHL-HIF system, prolyl hydroxylases (PHDs) are the intermediary proteins that initiate the degradation of HIFs. PHD isoform 3's (PHD3) role in ccRCC growth in vivo is poorly understood. Using viral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hypoxia-Inducible Factor-Proline Dioxygenases
Share to Basic Helix-Loop-Helix Transcription Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Renal Cell

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Sunitinib

Share to Von Hippel-Lindau Tumor Suppressor Protein

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 33799686
DOI: 10.3390/ijms22062849
PMCID: PMC8001211

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prolyl Hydroxylase 3 Knockdown Accelerates VHL-Mutant Kidney Cancer Growth In Vivo.PMID 33799686Read ↗

VHLinactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatmentSemantic proximity Read ↗

New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein.Semantic proximity Read ↗

Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel–Lindau-Deficient Renal CancerSemantic proximity Read ↗

The Von Hippel-Lindau Tumor Suppressor Gene and Kidney CancerSemantic proximity Read ↗

Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted TherapiesSemantic proximity Read ↗

Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathwaySemantic proximity Read ↗

SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosisSemantic proximity Read ↗

VHL and HIF signalling in renal cell carcinogenesisSemantic proximity Read ↗

Hypoxia-Induced SUMOylation of E3 Ligase HAF Determines Specific Activation of HIF2 in Clear-Cell Renal Cell CarcinomaSemantic proximity Read ↗

Treatment of kidney cancerSemantic proximity Read ↗

The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.Semantic proximity Read ↗

Lysyl oxidase drives ccRCC progression by coordinating HIF-2α transcription program with tumor microenvironmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.